LONDON, March 23, 2017 /PRNewswire/ --
Prima BioMed has presented encouraging early signs of efficacy from the TACTI-meltrial of IMP321 in combination with Keytruda, with one of the six melanoma patients in the first (1mg/kg) cohort experiencing a complete response. Recruitment in the second cohort is complete and the final cohort is expected to be fully recruited by
(Logo: http://photos.prnewswire.com/prnh/20130417/608168 )
Our valuation is unchanged at $192m, which is equal to ($9.24 per ADR) on an undiluted basis or $6.37/ADR after accounting for dilution from options, warrants and convertible notes. Guidance is that the cash balance of $12.6m at 31 December will be sufficient to fund operations through Q1 CY18, excluding any milestone payments from partners Novartis and GSK. Milestone revenue (we model ~$7m in FY18) would extend the cash runway.
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:
For more information please contact: Dennis Hulme Edison Investment Research +61(0)2-9258-1161
Dr Susie Jana Edison Investment Research +44(0)20-3077-5700 firstname.lastname@example.org
SOURCE Edison Investment Research
Subscribe to our Free Newsletters!